Denosumab treatment of inoperable or locally advanced giant cell tumor of bone

Borkowska,Aneta; Goryń,Tomasz; Pieńkowski,Andrzej; Wągrodzki,Michał; Jagiełło‑Wieczorek,Ewelina; Rogala,Paweł; Szacht,Milena; Rutkowski,Piotr

doi:10.3892/ol.2016.5246

Denosumab treatment of inoperable or locally advanced giant cell tumor of bone

Authors:
- Aneta Borkowska
- Tomasz Goryń
- Andrzej Pieńkowski
- Michał Wągrodzki
- Ewelina Jagiełło‑Wieczorek
- Paweł Rogala
- Milena Szacht
- Piotr Rutkowski
View Affiliations

Affiliations: Department of Radiation Oncology, Maria Skłodowska‑Curie Memorial Cancer Center and Institute of Oncology, 02‑781 Warsaw, Poland, Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Skłodowska‑Curie Memorial Cancer Center and Institute of Oncology, 02‑781 Warsaw, Poland, Department of Pathology, Maria Skłodowska‑Curie Memorial Cancer Center and Institute of Oncology, 02‑781 Warsaw, Poland
Published online on: October 12, 2016 https://doi.org/10.3892/ol.2016.5246
Pages: 4312-4318
Copyright: © Borkowska et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Giant cell tumor of bone (GCTB) is an osteolytic, locally aggressive tumor that rarely metastasizes and typically occurs in the bones. At present, the primary treatment for GCTB is curettage with local adjuvants. Giant cells express receptor activator of nuclear factor-κB ligand (RANKL). Denosumab, a RANKL inhibitor appears to present an effective therapeutic option in advanced cases of GCTB. The aim of the present study was to confirm the efficacy of denosumab in large group of patients with locally advanced GCTB. A total of 35 patients with histologically confirmed GCTB that were treated with denosumab with no participation in clinical trials between May 2013 and September 2015 were included in the present study. Denosumab treatment was administered until complete tumor resection was feasible or tumor progression or unacceptable toxicity had occurred. The mean denosumab treatment duration was 7.4 months. A total of 17 patients received surgery following denosumab treatment: 11 patients underwent wide en bloc resection with prosthesis implantation in 10 cases and 6 patients were treated with intralesional curettage. Tumor progression was observed in 2 patients that underwent intralesional curettage without prosthesis implantation. In addition, tumor progression was observed during denosumab treatment in 2 patients that had previously undergone radiotherapy. The overall 1‑year progression‑free survival rate was 92.8%. Thus, for patients with advanced, unresectable, progressive or symptomatic pretreated GCTB, denosumab provides a therapeutic option not previously available, which has become the standard therapy in multidisciplinary management of GCTB.

View Figures

View References

1	Amanatullah DF, Clark TR, Lopez MJ, Borys D and Tamurian RM: Giant cell tumor of bone. Orthopedics. 37:112–120. 2014. View Article : Google Scholar : PubMed/NCBI
2	Jagiello-Wieczorek E, Pieńkowski A and Rutkowski P: Denosumab for treating giant cell tumor of bone. Expert Opinion on Orphan Drugs. 3:1219–1229. 2015. View Article : Google Scholar
3	Thomas DM and Skubitz KM: Giant cell tumor of bone. Curr Opin Oncol. 21:338–344. 2009. View Article : Google Scholar : PubMed/NCBI
4	Skubitz KM: Giant cell tumor of bone: Current treatment options. Curr Treat Options Oncol. 15:507–518. 2014. View Article : Google Scholar : PubMed/NCBI
5	Campanacci M, Baldini N, Boriani S and Sudanese A: Giant-cell tumor of bone. J Bone Joint Surg Am. 69:106–114. 1987. View Article : Google Scholar : PubMed/NCBI
6	Dominkus M, Ruggieri P, Bertoni F, Briccoli A, Picci P, Rocca M and Mercuri M: Histologically verified lung metastases in benign giant cell tumours - 14 cases from a single institution. Int Orthop. 30:499–504. 2006. View Article : Google Scholar : PubMed/NCBI
7	van der Heijden L, Dijkstra PD, van de Sande MA, Kroep JR, Nout RA, van Rijswijk CS, Bovée JV, Hogendoorn PC and Gelderblom H: The clinical approach toward giant cell tumor of bone. Oncologist. 19:550–561. 2014. View Article : Google Scholar : PubMed/NCBI
8	Fletcher DM: WHO Classification of Tumours of Soft Tissue and Bone. 4th. IARC Press; Lyon: 2013
9	Greenspan A, Jundt G and Remagen W: Differential Diagnosis in Orthopaedic Oncology. 2nd. Lippincott Williams & Wilkins; Philadelphia, PA: 2007, PubMed/NCBI
10	Biermann JS: Updates in the treatment of bone cancer. J Natl Compr Canc Netw. 11:(Suppl 5). S681–S683. 2013.
11	Athanassou NA, Bensal M, Forsyth R, et al: Giant cell tumor of boneWHO Classification of Tumours of Soft Tissue and Bone. Fletcher CDM, Bridge JA, Hogendoorn PCW and Mertens F: IARC Press; Lyon: pp. 321–324. 2013
12	Hemingway F, Taylor R, Knowles HJ and Athanasou NA: RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II. Bone. 48:938–944. 2011. View Article : Google Scholar : PubMed/NCBI
13	Wu PF, Tang JY and Li KH: RANK pathway in giant cell tumor of bone: Pathogenesis and therapeutic aspects. Tumour Biol. 36:495–501. 2015. View Article : Google Scholar : PubMed/NCBI
14	Chakarun CJ, Forrester DM, Gottsegen CJ, Patel DB, White EA and Matcuk GR Jr: Giant cell tumor of bone: Review, mimics, and new developments in treatment. Radiographics. 33:197–211. 2013. View Article : Google Scholar : PubMed/NCBI
15	Thomas DM: RANKL, denosumab, and giant cell tumor of bone. Curr Opin Oncol. 24:397–403. 2012. View Article : Google Scholar : PubMed/NCBI
16	Roux S, Amazit L, Meduri G, Guiochon-Mantel A, Milgrom E and Mariette X: RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. Am J Clin Pathol. 117:210–216. 2002. View Article : Google Scholar : PubMed/NCBI
17	Morgan T, Atkins GJ, Trivett MK, Johnson SA, Kansara M, Schlicht SL, Slavin JL, Simmons P, Dickinson I, Powell G, et al: Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. Am J Pathol. 167:117–128. 2005. View Article : Google Scholar : PubMed/NCBI
18	Liao TS, Yurgelun MB, Chang SS, Zhang HZ, Murakami K, Blaine TA, Parisien MV, Kim W, Winchester RJ and Lee FY: Recruitment of osteoclast precursors by stromal cell derived factor-1 (SDF-1) in giant cell tumor of bone. J Orthop Res. 23:203–209. 2005. View Article : Google Scholar : PubMed/NCBI
19	Clézardin P: The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: Physiopathology and clinical implications. Bull Cancer. 98:837–846. 2011.(In French). PubMed/NCBI
20	Forsyth RG, De Boeck G, Baelde JJ, Taminiau AH, Uyttendaele D, Roels H, Praet MM and Hogendoorn PC: CD33+ CD14- phenotype is characteristic of multinuclear osteoclast-like cells in giant cell tumor of bone. J Bone Miner Res. 24:70–77. 2009. View Article : Google Scholar : PubMed/NCBI
21	Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van Loo P, Wedge DC, Cooke SL, Gundem G, Davies H, et al: Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet. 45:1479–1482. 2013. View Article : Google Scholar : PubMed/NCBI
22	Huvos AG: Bone TumorsDiagnosis, treatment and prognosis. 2nd. W.B. Saunders; Philadelphia, PA: 1990
23	Enneking WF: Staging musculoskeletal tumorsMusculoskeletal Tumor Surgery. Churchill Livingstone; New York, NY: pp. 87–88. 1983
24	Nielsen GP and Rosenberg AE: Diagnostic Pathology: Bone. Amirsys Lippincott Williams & Wilkins; Philadelphia, PA: 2012
25	Dufresne A, Derbel O, Cassier P, Vaz G, Decouvelaere AV and Blay JY: Giant-cell tumor of bone, anti-RANKL therapy. Bonekey Rep. 1:1492012. View Article : Google Scholar : PubMed/NCBI
26	Shehadeh A, Noveau J, Malawer M and Henshaw R: Late complications and survival of endoprosthetic reconstruction after resection of bone tumors. Clin Orthop Relat Res. 468:2885–2895. 2010. View Article : Google Scholar : PubMed/NCBI
27	Jeys LM, Suneja R, Chami G, Grimer RJ, Carter SR and Tillman RM: Impending fractures in giant cell tumors of the distal femur: Incidence and outcome. Int Orthop. 30:135–138. 2006. View Article : Google Scholar : PubMed/NCBI
28	Tse LF, Wong KC, Kumta SM, Huang L, Chow TC and Griffith JF: Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: A case-control study. Bone. 42:68–73. 2008. View Article : Google Scholar : PubMed/NCBI
29	Branstetter DG, Nelson SD, Manivel JC, Blay JY, Chawla S, Thomas DM, Jun S and Jacobs I: Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res. 18:4415–4424. 2012. View Article : Google Scholar : PubMed/NCBI
30	Steensma MR, Tyler WK, Shaber AG, Goldring SR, Ross FP, Williams BO, Healey JH and Purdue PE: Targeting the giant cell tumor stromal cell: Functional characterization and a novel therapeutic strategy. PLoS One. 8:e691012013. View Article : Google Scholar : PubMed/NCBI
31	Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, et al: Denosumab in patients with giant-cell tumour of bone: An open-label, phase 2 study. Lancet Oncol. 11:275–280. 2010. View Article : Google Scholar : PubMed/NCBI
32	López-Pousa A, Martín Broto J, Garrido T and Vázquez J: Giant cell tumour of bone: New treatments in development. Clin Transl Oncol. 17:419–430. 2015. View Article : Google Scholar : PubMed/NCBI
33	Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, Kroep J, Grimer R, Reichardt P, Rutkowski P, et al: Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: Interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 14:901–908. 2013. View Article : Google Scholar : PubMed/NCBI
34	National Institutes of Health, . Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
35	Rutkowski P, Ferrari S, Grimer RJ, Stalley PD, Dijkstra SP, Pienkowski A, Vaz G, Wunder JS, Seeger LL, Feng A, et al: Surgical downstaging in an open-label phase ii trial of denosumab in patients with giant cell tumor of bone. Ann Surg Oncol. 22:2860–2868. 2015. View Article : Google Scholar : PubMed/NCBI
36	Bukata SV, Sudan M, Mendanha W, et al: Considerations for long-term maintenance treatment with denosumab for stable inoperable Giant Cell Tumor: Making a case for spacing of doses after initial response. Connective Tissue Oncology Society: Abstract 047. 2015.